Sei Investments Co. grew its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 43.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 408,043 shares of the company's stock after purchasing an additional 124,558 shares during the quarter. Sei Investments Co. owned about 0.20% of Cellebrite DI worth $8,989,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds also recently made changes to their positions in the company. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Cellebrite DI by 9.7% during the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 190,012 shares of the company's stock worth $4,186,000 after purchasing an additional 16,792 shares during the period. Teacher Retirement System of Texas purchased a new position in shares of Cellebrite DI in the 4th quarter worth approximately $442,000. Counterpoint Mutual Funds LLC grew its stake in Cellebrite DI by 9.6% in the 4th quarter. Counterpoint Mutual Funds LLC now owns 86,776 shares of the company's stock valued at $1,912,000 after purchasing an additional 7,569 shares during the period. Polen Capital Management LLC bought a new stake in Cellebrite DI in the fourth quarter worth about $222,000. Finally, Telemark Asset Management LLC increased its stake in shares of Cellebrite DI by 25.0% during the 4th quarter. Telemark Asset Management LLC now owns 500,000 shares of the company's stock worth $11,015,000 after purchasing an additional 100,000 shares during the last quarter. Institutional investors own 45.88% of the company's stock.
Analyst Upgrades and Downgrades
CLBT has been the subject of several recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $28.00 price objective on shares of Cellebrite DI in a report on Wednesday. Lake Street Capital increased their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, February 14th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $24.00 to $28.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and a consensus price target of $23.43.
Get Our Latest Analysis on CLBT
Cellebrite DI Stock Down 5.3 %
Shares of CLBT traded down $1.06 during trading hours on Thursday, hitting $18.77. The company had a trading volume of 1,126,661 shares, compared to its average volume of 1,396,945. The firm has a market cap of $4.49 billion, a P/E ratio of -13.50, a P/E/G ratio of 4.27 and a beta of 1.52. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The stock's 50 day moving average price is $20.53 and its 200 day moving average price is $19.94.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, research analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading

Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.